Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
BMS Adds Tau Antibody With iPierian Deal
by Lisa M. Jarvis
May 5, 2014
| A version of this story appeared in
Volume 92, Issue 18
Bristol-Myers Squibb has paid $175 million in cash, with the promise of up to $550 million in milestones, to acquire privately held iPierian. With the deal, BMS gains the rights to IPN007, an antibody aimed at progressive supranuclear palsy (PSP) and other neurodegenerative diseases associated with the buildup of tau, a protein believed to help regulate the activity of brain cells. IPN007 is expected to enter Phase I studies in early 2015 as a treatment for PSP, but it has the potential to be useful in treating Alzheimer’s disease.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter